Monthly Archives: July 2016

Home/2016/July

LOXO-101 receives breakthrough therapy designation from FDA for solid tumors with NTRK gene fusions

Loxo Oncology  announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of unresectable or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusions. This [...]

By |2020-02-21T14:56:38-05:00July 21st, 2016|News, Research|

Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well

In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]

By |2018-10-30T09:41:06-04:00July 19th, 2016|Clinical Trials, News, Research|

Ignyta Announces Results for Potential New Cancer Treatment

Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]

By |2020-02-21T15:04:32-05:00July 12th, 2016|Clinical Trials, News, Research|
Go to Top